A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficac
Bayer has joined forces with Google Cloud to continue development of an artificial intelligence-powered platform to help radiologists diagnose patients quicker and more ef
Bayer chief executive Bill Anderson has followed through on a pledge to streamline the group’s management, starting at the very top with a big reduction in the pharma unit
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati
Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the ther